OTCMKTS:MYMX Mymetics (MYMX) Stock Price, News & Analysis $0.0003 0.00 (0.00%) As of 10/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Mymetics Stock (OTCMKTS:MYMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mymetics alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.0003▼$0.0003VolumeN/AAverage Volume13 shsMarket Capitalization$45.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mymetics (OTCMKTS: MYMX) is a clinical-stage biotechnology company specializing in the development of prophylactic and therapeutic vaccines for infectious diseases. The company’s proprietary virosome‐based delivery platform is designed to present antigens in a lipid bilayer, mimicking the natural presentation of viruses to the immune system. This approach aims to stimulate robust and durable humoral and cellular responses while maintaining a favorable safety profile. The company’s pipeline includes candidates targeting viral pathogens such as influenza, herpes simplex virus (HSV), and human immunodeficiency virus (HIV). Mymetics’ lead programs have advanced through preclinical and early‐stage clinical evaluations, demonstrating proof of concept for its virosome technology. Additional research collaborations have explored applications in pandemic preparedness and emerging infectious diseases. Founded in 1998, Mymetics is headquartered in Belgium with a subsidiary in the United States to support North American development and regulatory activities. The company has focused on leveraging its virosome platform to form strategic partnerships, aiming to accelerate late‐stage clinical trials and commercialization efforts. Its management team comprises professionals with experience in vaccine research, clinical development, and regulatory affairs, guiding the company’s strategic direction in global markets.AI Generated. May Contain Errors. Read More Receive MYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mymetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYMX Stock News HeadlinesSp Bmv Ipc Esg Tilted Heavy (MYMX)October 17, 2024 | investing.comPLTXF PlantX Life Inc.March 29, 2024 | seekingalpha.comIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The company delivered record-breaking revenues in 2024 and Q1 2025, including $72.5 million in net revenue for Q1 — a 73% increase over the prior year — and six consecutive quarters of positive adjusted EBITDA. With cash reserves rising to $30.8 million and a growing patent portfolio of 58 issued and 68 pending patents, BSEM is scaling profitably while advancing its proprietary BioREtain® technology, which has shown clinically superior results for chronic, non-healing wounds. National recognition is adding to the momentum, with CEO Jason Matuszewski named EY Entrepreneur of the Year 2025 Florida Award winner, validating the leadership driving this high-growth MedTech powerhouse.October 16 at 2:00 AM | Huge Alerts (Ad)Mymetics Corporation (MYMXD) Stock Historical Prices & Data - Yahoo FinanceFebruary 2, 2024 | finance.yahoo.comMymetics Stock (OTC:MYMX) Dividends: History, Yield and DatesDecember 30, 2023 | benzinga.comOriole Resources project in Cameroon delivers high-grade gold resultsMarch 1, 2023 | lse.co.ukMymetics Stock (OTC:MYMX), Short Interest ReportNovember 15, 2022 | benzinga.comMymetics Corporation (MYMX)October 11, 2022 | finance.yahoo.comSee More Headlines MYMX Stock Analysis - Frequently Asked Questions How have MYMX shares performed this year? Mymetics' stock was trading at $0.0010 at the start of the year. Since then, MYMX stock has decreased by 70.0% and is now trading at $0.0003. How do I buy shares of Mymetics? Shares of MYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mymetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mymetics investors own include Dynavax Technologies (DVAX), Fujitsu (FJTSY), Genocea Biosciences (GNCA), Maxar Technologies (MAXR), Revance Therapeutics (RVNC), Axcelis Technologies (ACLS) and Allied Gaming & Entertainment (AGAE). Company Calendar Today10/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:MYMX CIK927761 Webwww.mymetics.com Phone(121) 653-4535Fax41-21-653-2473Employees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.08 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares150,000Free Float144,000Market Cap$45.00 OptionableNot Optionable Beta2.51 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:MYMX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mymetics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mymetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.